GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Pharmaceutical Product Development Inc. (PPDI) CEO David L Grange sells 51,753 Shares

November 04, 2010 | About:
insider

insider

56 followers
CEO of Pharmaceutical Product Development Inc. (PPDI) David L Grange sells 51,753 shares of PPDI on 11/03/2010 at an average price of $25.71 a share.

Pharmaceutical Product Development Inc. has a market cap of $3.04 billion; its shares were traded at around $25.77 with a P/E ratio of 27.2 and P/S ratio of 2.2. The dividend yield of Pharmaceutical Product Development Inc. stocks is 2.3%. Pharmaceutical Product Development Inc. had an annual average earning growth of 17.1% over the past 10 years. GuruFocus rated Pharmaceutical Product Development Inc. the business predictability rank of 3.5-star.

PPDI is in the portfolios of Third Avenue Management, John Hussman of Hussman Economtrics Advisors, Inc., John Hussman of Hussman Economtrics Advisors, Inc., Chuck Royce of Royce& Associates, Bruce Kovner of Caxton Associates, Richard Aster Jr of Meridian Fund, Jeremy Grantham of GMO LLC, George Soros of Soros Fund Management LLC, Jean-Marie Eveillard of First Eagle Investment Management, LLC.


This is the insider trade history vs. stock price of PPDI. For the complete insider trading history of PPDI, click here.




Directors and Officers Recent Trades:



  • Sell: Director Ernest Mario sold 26,726 shares of PPDI stock on 08/09/2010 at the average price of 25.12. Ernest Mario owns at least 442,086 shares after this. The price of the stock has increased by 2.59% since.


About the author:

insider
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK